Methods of treating prostate cancer with GnRH antagonist
AssigneeFerring B.V.
InventorsTine Kold Olesen, Bo-Eric Persson, Per Cantor, Egbert A. van der Meulen, Jens-Kristian Slott Jensen
Life of this patent
Estimating the term…
Abstract
The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
Claims24
A method of treating advanced stage prostate cancer in a human subject with a decreased likelihood of developing arthralgia during treatment as compared to treatment with a gonadotrophin releasing hormone (GnRH) agonist, comprising:
- administering an initial dose of 240 mg of degarelix to the subject as two subcutaneous injections of 120 mg each at a concentration of 40 mg/mL on the same day, and
- administering a maintenance dose of 80 mg of degarelix at a concentration of 20 mg/mL to the subject as one subcutaneous injection, wherein the maintenance dose is administered approximately every 28 days after the previous dose of degarelix for a duration of treatment,
- wherein the treated subject has a decreased likelihood of developing arthralgia during treatment compared to treatment with a GnRH agonist.
A method of treating advanced stage prostate cancer in a human subject and achieving an at least 50% decrease in serum prostate specific antigen (PSA) level by about day 14 of treatment, comprising:
- administering an initial dose of 240 mg of degarelix to the subject as two subcutaneous injections of 120 mg each at a concentration of 40 mg/mL on the same day, and
- administering a maintenance dose of 80 mg of degarelix at a concentration of 20 mg/mL to the subject as one subcutaneous injection, wherein the maintenance dose is administered approximately every 28 days after the previous dose of degarelix for a duration of treatment,
- wherein the treated subject has at least a 50% decrease in serum PSA level by about day 14 of treatment.
A method of treating advanced stage prostate cancer in a human subject with a decreased likelihood of urinary tract infection during treatment as compared to treatment with a gonadotrophin releasing hormone (GnRH) agonist, comprising:
- administering an initial dose of 240 mg of degarelix at a concentration of 40 mg/mL to the subject as two subcutaneous injections of 120 mg each on the same day, and
- administering a maintenance dose of 80 mg of degarelix at a concentration of 20 mg/mL to the subject as one subcutaneous injection, wherein the maintenance dose is administered approximately every 28 days after the previous dose of degarelix for a duration of treatment,
- wherein the treated subject has a decreased likelihood of urinary tract infection during treatment compared to treatment with a GnRH agonist.
Dependencies are inferred from the claim text.